[Alemtuzumab for relapsing-remitting multiple sclerosis : Results of two randomized controlled phase III studies.] Klotz L, Meuth SG, Kieseier B, Wiendl H Nervenarzt. 2013 Jun 23. PMID: 23793409. Abstract CommentRecommendBookmarkWatch